New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia

Pharmacotherapy
Zach R ClickAdebayo Ogunniyi

Abstract

Advancements in the treatment of acute myeloid leukemia (AML) have been sparse during the past several decades, and the disease continues to have a poor prognosis. However, in 2017 alone, four new medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of AML reached the market. Midostaurin, liposomal cytarabine and daunorubicin, enasidenib, and gemtuzumab ogozamicin all showed benefit in respective clinical trials to gain approval for the treatment of AML in various patient populations. Additionally, many phase II and III clinical trials are currently ongoing to assess the safety and efficacy of other potential therapies for the treatment of AML. In this review, we summarize the results of the landmark clinical trials associated with the newly approved agents as well as the current ongoing clinical trials for the treatment of AML. A literature search was performed to retrieve data on agents currently being studied for use. Although the overall prognosis for patients with AML remains poor, the addition of the newly FDA-approved medications is a step in the right direction for a disease state that has proved difficult to treat.

References

Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L SieversUNKNOWN Mylotarg Study Group
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J FeldmanArthur C Louie
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesMark Levis
Oct 3, 2013·Cancer Chemotherapy and Pharmacology·Catherine DutreixYanfeng Wang
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T M KadiaH Kantarjian
Oct 23, 2016·Clinical Lymphoma, Myeloma & Leukemia·Mona HassaneinRiad El Fakih
Dec 22, 2016·European Journal of Haematology·Amir T Fathi, Yi-Bin Chen
Mar 14, 2017·Current Treatment Options in Oncology·Prithviraj BoseJorge E Cortes
Jun 8, 2017·Blood·Eytan M SteinMartin S Tallman
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner
Nov 23, 2017·Leukemia & Lymphoma·Mrinal M Patnaik
Dec 2, 2017·British Journal of Haematology·Sabine Kayser, Mark J Levis

❮ Previous
Next ❯

Citations

May 18, 2019·American Society of Clinical Oncology Educational Book·Michael HeuserJessica K Altman
Dec 5, 2019·International Journal of Molecular Sciences·Jonathan R SillarMatthew D Dun
Apr 21, 2020·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Hiromi OkamotoHiroshi Kuga
Aug 28, 2020·Nature Communications·Raquel FerreiraLino Ferreira
Jun 11, 2019·American Journal of Hematology·Daniel A Pollyea
Mar 7, 2020·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Daniel R RichardsonJohn F P Bridges

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
Julian R DavisBrian A Jonas
© 2022 Meta ULC. All rights reserved